ImmunoVaccine Inc. | Ownership
Companies that own ImmunoVaccine Inc.
Ruffer LLP
6,121,259
14.26%
964,044
0.35%
03/29/2018
Fidelity (Canada) Asset Management ULC
2,675,000
6.23%
2,675,000
0.02%
06/30/2018
Industrial Alliance Investment Management, Inc.
252,155
0.59%
-6,400
0.02%
08/31/2018
Intact Investment Management, Inc.
242,218
0.56%
242,218
0.05%
06/30/2018
DWS Investment GmbH
101,713
0.24%
101,713
0%
06/30/2018
Guardian Capital Advisors LP
85,132
0.2%
85,132
0.07%
06/30/2018
IA Clarington Investments, Inc.
83,218
0.19%
0
0.02%
08/31/2018
Barometer Capital Management, Inc.
76,969
0.18%
76,969
0.03%
12/31/2017
Timelo Investment Management, Inc.
66,406
0.16%
66,406
0.56%
06/30/2017
Renaissance Technologies LLC
44,813
0.1%
44,813
0%
06/30/2018
| Address |
130 Eileen Stubbs Avenue
Dartmouth Nova Scotia B3B 2C4
Canada
|
|
Employees
|
- |
| Website |
http://www.imv-inc.com |
| Updated |
07/08/2019 |
| IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada. |
